Table 5.
Details of included clinical trials
| Type of modification | Type of immune effector cells | Trial names (cumulative follow-up, y) | Trials included (NCI no.) | No. of patients | No. of SMs | Median time to last detected transgene, mo (range)* |
|---|---|---|---|---|---|---|
| Donor marked | EBVSTs | ETNA (287.6) | NCT00058812 | 26 | 3 | 44.5 (0-105) |
| Auto marked | EBVSTs | ANGEL and ANGELA (19.1) | NCT00058617 | 7 | 2 | Up to 2 y |
| iCasp9 | iCasp9 T cell | CASPALLO (48.3) DOTTI (28.0) |
NCT00710892 NCT01494103 |
24 | 0 | 12 (0.25-108) |
| Dominant negative receptor | DNR TGF-β cells | TGFB (38.1) RESIST NPC (17.9) HESTIA (13.3) |
NCT00675571 NCT02065362 NCT02379520 |
28 | 3 | 6 (0.5-72) |
| CAR T cell | GD2 CAR T cells | NESTLES (93.1) GRAIN (30.0) GAIL-N (10.3) VEGAS (16.2) |
NCT00085930 NCT01822652 NCT03635632 NCT01953900 NCT03294954 |
51 | 1 | 3 (0-108) |
| CD19 CAR T cells | CRETI (59.2) ATECRAB (8.5) SAGAN (47.0) CARSPASCIO (15.5) MULTIPRAT (55.6) |
NCT00586391 NCT00709033 NCT01853631 NCT02050347 NCT00840853 |
63 | 6 | 6 (0-96) | |
| HER2 CAR T cells | HERCREEM (20.6) HERT-GBM (15.9) HEROS (71.1) |
NCT00889954 NCT01109095 NCT00902044 |
71 | 1 | 1.5 (0-84) | |
| CD30 CAR T cells | CAR CD30 (18.6) CART CD30 (30.3) RELY 30 (26.0) |
NCT01192464 NCT01316146 NCT02917083 |
33 | 0 | 6 (0-24) | |
| Glypican 3 CAR T cells | GLYCAR (1.8) GAP (3.6) |
NCT02905188 NCT02932956 |
8 | 0 | 3 (2-12) | |
| CD5 CAR T cells | MAGENTA (6.7) | NCT03081910 | 11 | 0 | 3 (0.75-30) | |
| κ CAR T cells | CHARKALL (45.1) | NCT00881920 | 18 | 2† | 6 (0.25-60) |
DNR, dominant-negative receptor; NCI, National Cancer Institute; TGF, transforming growth factor.
*
Time to last detected transgene was calculated from the time of last infusion (if patient received >1 infusion) to time to any positive transgene value detected by qPCR.
†
Two subsequent malignancies were reported in a patient who received both CD19 and κ CAR T cells.